Results for infused with translation from English to Maltese

immunosuppressive therapy also affects immunocompetent cells as such infused with zalmoxis.
terapija immunosuppressiva taffettwa wkoll ċelluli immunokompetenti bħal dawk infużi b’zalmoxis.

elaprase should not be infused with other medicinal products in the infusion tubing.
elaprase ma għandux jingħata bħala infużjoni ma’ prodotti mediċinali oħrajn fit-tubu tal-infużjoni.

it is recommended that xigris be infused with an infusion pump to accurately control the infusion rate.
huwa rrakkomandat li xigris jiġi infuż b’pompa għall-infużjoni sabiex tiġi kkontrollata bi preċiżjoni r-rata ta’ infużjoni.

mycamine must not be mixed or co-infused with other medicinal products except those mentioned below.
mycamine m’għandux jiġi mħallat jew infuż ma’ prodotti mediċinali oħra għajr dawk imsemmija hawn taħt.

vpriv should not be infused with other medicines in the same infusion as the compatibility in solution with other medicines has not been evaluated.
vpriv m’għandux jingħata f’infużjoni ma’ prodotti oħrajn minħabba li l-kompatibilità fis-soluzzjoni ma’ prodotti oħrajn ma ġietx evalwata.

this medicinal product must not be mixed or co-infused with other medicinal products except those mentioned in section 6.6.
dan il-prodott mediċinali m’għandux jiġi mħallat jew jingħata b’infużjoni ma’ prodotti mediċinali oħra għajr dawk imsemmija f’sezzjoni 6.6.

drotrecogin alfa (activated) that is present in a blood or plasma sample drawn from a patient who is being infused with the drug will be gradually neutralized by endogenous plasma protease inhibitors present in the sample.
drotrecogin alfa (attivat) li jkun preżenti f’kampjun tad-demm jew tal- plażma meħud minn pazjent li jkun qiegħed jieħu infużjoni tal-mediċina jiġi newtralizzat bil-mod il- mod permezz ta’ inibituri endoġeni tal-proteażi tal-plażma li jkunu preżenti fil-kampjun.

severe iars have been reported in patients with pre-existent severe underlying upper airway involvement and therefore specifically these patients should continue to be closely monitored and only be infused with aldurazyme in an appropriate clinical setting where resuscitation equipment to manage medical emergencies would be readily available.
iars severi kienu rrappurtati f’pazjenti b’disturb bażiku li kien jeżisti minn qabel fin-naħa ta’ fuq tal- passaġġ tan-nifs, u għalhekk, dawn il-pazjenti għandhom speċifikament ikunu mmonitorjati mill-qrib, u jingħataw l-infużjoni b’aldurazyme biss fi sfond kliniku adattat, fejn tagħmir tar-risuxitazzjoni għandu jkun disponibbli fil-pront, biex emerġenzi mediċi jkunu jistgħu jiġu mmaniġġjati.